Physician profile
Bryce C Bushe
NPI 1114338829
$2,275.75
in general payments reported to CMS, 2019-2025
18 companies · $365 in 2025
The $365 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $319 · 2021: $352 · 2022: $86.76 · 2023: $228 · 2024: $641 · 2025: $365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,233.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $471.64 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $359.41 | 2023-2024 | Zeposia |
| Erbe USA INC | $294.44 | 2019-2025 | Vio3apc3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $252.74 | 2019-2021 | |
| Medtronic, INC. | $229.57 | 2023-2025 | Pillcam, Gi Genius, Bravo |
| Boston Scientific Corporation | $136.92 | 2020-2021 | |
| Genzyme Corporation | $117.38 | 2024 | |
| Lilly USA, LLC | $105.21 | 2024 | Omvoh |
| Janssen Biotech, INC. | $76.61 | 2024-2025 | Tremfya |
| Covidien LP | $49.83 | 2020 | |
| Madrigal Pharmaceuticals | $38.09 | 2025 | Rezdiffra |
| Celgene Corporation | $33.57 | 2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $27.48 | 2023 | |
| Olympus America INC. | $20.09 | 2025 | Evis Exera III Colonovideoscope |
| Takeda Pharmaceuticals U.S.A., INC. | $18.57 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $17.49 | 2019 | |
| Braintree Laboratories, INC. | $15.21 | 2021 | |
| Merck Sharp & Dohme LLC | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryce Bushe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.